Total Payments
$1.8M
2024 Payments
$292,893
Companies
8
Transactions
201
Payment Breakdown by Category
Research$1.4M (76.3%)
Consulting$418,684 (23.7%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $1.4M | 136 | 76.3% |
| Consulting Fee | $418,684 | 65 | 23.7% |
Payments by Type
Research
$1.4M
136 transactions
General
$418,684
65 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Vanda Pharmaceuticals Inc. | $1.3M | 132 | $0 (2024) |
| AMAG Pharmaceuticals, Inc. | $178,923 | 25 | $0 (2023) |
| Merck Sharp & Dohme LLC | $114,680 | 10 | $0 (2023) |
| Sandoz Inc. | $49,531 | 15 | $0 (2020) |
| Janssen Research & Development, LLC | $38,363 | 5 | $0 (2021) |
| Heron Therapeutics, Inc. | $32,868 | 9 | $0 (2021) |
| Takeda Pharmaceuticals U.S.A., Inc. | $10,918 | 3 | $0 (2024) |
| PFIZER INC. | $1,270 | 2 | $0 (2021) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $292,893 | 24 | Vanda Pharmaceuticals Inc. ($281,975) |
| 2023 | $598,764 | 54 | Vanda Pharmaceuticals Inc. ($427,734) |
| 2022 | $151,265 | 11 | Vanda Pharmaceuticals Inc. ($151,265) |
| 2021 | $38,948 | 13 | Janssen Research & Development, LLC ($15,503) |
| 2020 | $289,843 | 37 | Vanda Pharmaceuticals Inc. ($264,938) |
| 2019 | $132,860 | 25 | AMAG Pharmaceuticals, Inc. ($70,890) |
| 2018 | $132,831 | 16 | Vanda Pharmaceuticals Inc. ($83,895) |
| 2017 | $132,090 | 21 | Vanda Pharmaceuticals Inc. ($71,613) |
All Payment Transactions
201 individual payment records from CMS Open Payments — Page 1 of 9
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/09/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $900.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 12/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $1,897.50 | Research |
| Study: POST-OP RECOVERY - OREXIN | ||||||
| 11/15/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $6,100.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 11/04/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $2,475.00 | Research |
| Study: POST-OP RECOVERY - OREXIN | ||||||
| 09/18/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 09/09/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $3,275.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 08/12/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $15,800.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 07/08/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $2,500.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 06/24/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $2,450.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 05/24/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $1,250.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 05/10/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $250.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 04/05/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $25,000.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 04/05/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $18,000.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 04/05/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $6,250.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 04/05/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $3,150.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 03/15/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $68,500.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 03/07/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $250.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 03/06/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | — | Cash or cash equivalent | $6,545.00 | Research |
| Study: POST-OP RECOVERY - OREXIN | ||||||
| 02/07/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $42,800.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 02/07/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $16,175.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 02/07/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $14,175.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 01/12/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $29,450.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 01/12/2024 | Vanda Pharmaceuticals Inc. | — | — | Cash or cash equivalent | $700.00 | Research |
| Study: EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | ||||||
| 01/10/2024 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $24,750.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
| 12/15/2023 | Vanda Pharmaceuticals Inc. | FANAPT (Drug) | — | Cash or cash equivalent | $32,400.00 | Research |
| Study: EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER • Category: SCHIZOPHRENIA | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| EVALUATING THE SAFETY AND EFFICACY OF TRADIPITANT VS. PLACEBO IN IDIOPATHIC AND DIABETIC GASTROPARESIS | Vanda Pharmaceuticals Inc. | $443,782 | 24 |
| EVALUATION OF EFFICACY AND SAFETY OF ILOPERIDONE IN THE TREATMENT OF BIPOLAR I DISORDER | Vanda Pharmaceuticals Inc. | $188,775 | 16 |
| AN OPEN-LABEL, SEQUENTIAL DOSE ESCALATION COHORT STUDY TO EVALUATE THE SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF ILOPERIDONE LONG ACTING INJECTABLE IN SUBJECTS WITH SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $169,441 | 29 |
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE III STUDY TO ASSESS THE EFFICACY OF TRADIPITANT IN RELIEVING SYMPTOMS OF GASTROPARESIS | Vanda Pharmaceuticals Inc. | $160,880 | 10 |
| Study of the Pharmacokinetics and Safety of Tasimelteon in Children and Adolescents | Vanda Pharmaceuticals Inc. | $118,788 | 16 |
| A STUDY TO EVALUATEILOPERIDONELONG-ACTING INJECTION (LAI) FOR THE TREATMENT OF SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $75,485 | 7 |
| A STUDY TO EVALUATE ILOPERIDONE LONG-ACTING INJECTION (LAI) FOR THE TREATMENT OF SCHIZOPHRENIA | Vanda Pharmaceuticals Inc. | $72,833 | 16 |
| An Open-label, Sequential Dose Escalation Cohort Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Iloperidone Long Acting Injectable in Subjects with Schizophrenia | Vanda Pharmaceuticals Inc. | $41,870 | 7 |
| Tradipitant in Treatment-resistant Pruritus Associated With Atopic Dermatitis | Vanda Pharmaceuticals Inc. | $36,720 | 1 |
| EVALUATING THE EFFECTS OF TASIMELTEON VS PLACEBO ON SLEEP DISTURBANCES IN SMS | Vanda Pharmaceuticals Inc. | $19,486 | 3 |
| POST-OP RECOVERY - OREXIN | Takeda Pharmaceuticals U.S.A., Inc. | $10,918 | 3 |
| A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase III Study to Assess the Efficacy of Tradipitant in Relieving Symptoms of Gastroparesis | Vanda Pharmaceuticals Inc. | $7,448 | 1 |
| EVALUATING THE EFFECTS OF TRADIPITANT VS. PLACEBO IN ATOPIC DERMATITIS | Vanda Pharmaceuticals Inc. | $3,115 | 1 |
| MOD4023 OPKO CLINICAL PUBLICATION PROGRAM | PFIZER INC. | $1,270 | 2 |
About Dr. Dennis Fisher, M.D
Dr. Dennis Fisher, M.D is a Contractor healthcare provider based in San Francisco, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 09/20/2015. The National Provider Identifier (NPI) number assigned to this provider is 1740659747.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Dennis Fisher, M.D has received a total of $1.8M in payments from pharmaceutical and medical device companies, with $292,893 received in 2024. These payments were reported across 201 transactions from 8 companies. The most common payment nature is "" ($1.4M).
Ad
Practice Information
- Specialty Contractor
- Location San Francisco, CA
- Active Since 09/20/2015
- Last Updated 09/20/2015
- Taxonomy Code 171W00000X
- Entity Type Individual
- Practice Solo Practitioner
- NPI Number 1740659747
Products in Payments
- FANAPT (Drug) $506,534
- Hetlioz (Drug) $118,788
- FERAHEME (Drug) $105,715
- MAKENA (Drug) $68,753
- Fanapt (Drug) $41,870
- SALMETEROL XINAFOATE/FLUTICA (Drug) $36,789
- HETLIOZ (Drug) $23,806
- HTX-011 (Drug) $22,568
- Zynrelef (Drug) $10,300
- BREMELANOTIDE (Drug) $4,455
- SALMETEROL XINAFOATE/FLUTICASONE PROPIONATE (Drug) $4,144
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Contractor Doctors in San Francisco
Dr. Kun Huang, M.d, M.D
Contractor — Payments: $61.87
Contractor $61.87
Janet Green Babb, M.s., P.t, M.S., P.T
Contractor
Contractor
Mr. Wayne Ng, Cmt, CMT
Contractor
Contractor
Joselle Gacusan, Cmt, CMT
Contractor
Contractor
Mrs. Gretchen Cheng, Otr/L, OTR/L
Contractor
Contractor
Joanie Hooper, Otr/L, OTR/L
Contractor
Contractor